Acrivon Therapeutics (ACRV) vs Equillium (EQ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Acrivon Therapeutics (ACRV) has outperformed Equillium (EQ) over the past year, losing 9.4% versus a loss of 18.5%. Equillium is the larger company by market cap ($75.5 million vs $70.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | EQ |
|---|---|---|
| Share price | $1.64 | $1.19 |
| Market cap | $70.28M | $75.46M |
| 1-day change | -6.82% | -9.85% |
| YTD return | -31.95% | -23.23% |
| 1-year return | -9.39% | -18.49% |
| 5-year return | — | -79.69% |
| EPS (TTM) | $-1.88 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-77.91M | $-22.40M |
| 52-week high | $3.56 | $3.54 |
| 52-week low | $1.27 | $0.76 |
| Distance from 52-week high | -53.93% | -66.38% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +601.22% | +619.33% |
| Average volume | 318.58K | 547.91K |
| Shares outstanding | 42.85M | 63.41M |
| Employees | 74 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
ACRV vs EQ FAQ
Which is bigger, Acrivon Therapeutics or Equillium?
Equillium (EQ) is larger, with a market capitalization of $75.46M compared with $70.28M for Acrivon Therapeutics (ACRV).
Which stock has performed better over the past year, ACRV or EQ?
ACRV returned -9.39% over the past 12 months, compared with -18.49% for EQ (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and Equillium in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.